The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XX.e

Pneumocystis jiroveci pneumonia

Publications

Haeusler GM, Slavin MA, Seymour JF, Lingaratnam S, Teh BW, Tam CS, Thursky KA, Worth LJ

Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.

European journal of haematology 2013 Aug;91;157-63 — 2013 Aug — 157-63

Kulke MH, Vance EA

Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997 Aug;25;215-8 — 1997 Aug — 215-8

Cheson BD, Samlowski WE, Tang TT, Spruance SL

Value of open-lung biopsy in 87 immunocompromised patients with pulmonary infiltrates.

Cancer 1985 Jan 15;55;453-9 — 1985 Jan 15 — 453-9